Chargement en cours...
Expanding role of lenalidomide in hematologic malignancies
Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic syndrome, and mantle cell lymphoma. In addition, it has clinical activity in lymphoproliferative disorders and acute myeloid leukemia...
Enregistré dans:
| Publié dans: | Cancer Manag Res |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4427066/ https://ncbi.nlm.nih.gov/pubmed/25999761 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S81310 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|